Abstract Background To understand the kinetics of immune responses with different dosing gaps of the AZD1222 vaccine, we compared antibody and T cell responses in two cohorts with two different dosing gaps. Methods Antibodies to the SARS‐CoV‐2 virus were assessed in 297 individuals with a dosing gap of 12 weeks, sampled 12 weeks post second dose (cohort 1) and in 77 individuals with a median dosing gap of 21.4 weeks (cohort 2) sampled 6 weeks post second dose. ACE2‐blocking antibodies (ACE2‐blocking Abs), antibodies to the receptor‐binding domain (RBD) of variants of concern (VOC), and ex vivo T cell responses were assessed in a subcohort. Results All individuals (100%) had SARS‐CoV‐2‐specific total antibodies and 94.2% of cohort 1 and 97.1% of cohort 2 had ACE2‐blocking Abs. There was no difference in antibody titers or positivity rates in different age groups in both cohorts. The ACE2‐blocking Abs ( p  < .0001) and antibodies to the RBD of the VOCs were significantly higher in cohort 2 compared to cohort 1. 41.2% to 65.8% of different age groups gave a positive response by the hemagglutination assay to the RBD of the ancestral virus and VOCs in cohort 1, while 53.6%–90% gave a positive response in cohort 2. 17/57 (29.8%) of cohort 1 and 17/29 (58.6%) of cohort 2 had ex vivo interferon (IFN)γ ELISpot responses above the positive threshold. The ACE2‐blocking antibodies (Spearman's r  = .46, p  = .008) and ex vivo IFNγ responses (Spearman's r  = .71, p  < .0001) at 12 weeks post first dose, significantly correlated with levels 12 weeks post second dose. Conclusions Both dosing schedules resulted in high antibody and T cell responses post vaccination, although those with a longer dosing gap had a higher magnitude of responses, possibly as immune responses were measured 6 weeks post second dose compared to 12 weeks post second dose.